Use of cannabinoids in the treatment of epilepsy
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
1. A method of treating seizures in a patient having Lennox-Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex, or Doose Syndrome, comprising orally administering to the patient a pharmaceutical formulation comprising a cannabidiol (CBD) drug substance,
wherein the CBD is present in the pharmaceutical formulation at a concentration of about 100 mg/mL,
wherein the drug substance comprises CBD and at least one of (i) cannabidivarin (CBDV) at not more than 1.0% w/w based on the weight of the drug substance, (ii) delta-9 tetrahydrocannabinol (Δ 9 THC) at not more than 0.15% w/w based on the weight of the drug substance, or (iii) cannabidiol-C4 (CBD-C4) at not more than 0.5% w/w based on the weight of the drug substance, and
wherein the patient is administered a starting dose of CBD of about 5 mg/kg/day, and after administering the starting dose of CBD, the starting dose is gradually increased by about 5 mg/kg increments up to a maximum of about 25 mg/kg/day.
2. The method of claim 1 , wherein the drug substance comprises at least two of (i) CBDV at not more than 1.0% w/w based on the weight of the drug substance, (ii) Δ 9 THC at not more than 0.15% w/w based on the weight of the drug substance, or (iii) CBD-C4 at not more than 0.5% w/w based on the weight of the drug substance.
3. The method of claim 1 , wherein the drug substance comprises (i) CBDV at not more than 1.0% w/w based on the weight of the drug substance, (ii) Δ 9 THC at not more than 0.15% w/w based on the weight of the drug substance, and (iii) CBD-C4 at not more than 0.5% w/w based on the weight of the drug substance.
4. The method of claim 3 , wherein the drug substance comprises not more than 0.15% w/w cannabidiolic acid (CBDA) based on the weight of the drug substance.
5. The method of claim 4 , wherein the starting dose of CBD is increased to a dose ranging from about 10 mg/kg/day to about 25 mg/kg/day.
6. The method of claim 1 , wherein the administering reduces the number of seizures by at least 50% compared to the number of seizures experienced during a baseline period before CBD was administered.
7. The method of claim 4 , wherein the administering reduces the number of seizures by at least 50% compared to the number of seizures experienced during a baseline period before CBD was administered.
8. The method of claim 5 , wherein the administering reduces the number of seizures by at least 50% compared to the number of seizures experienced during a baseline period before CBD was administered.
9. The method of claim 6 , wherein the seizures are atonic seizures, tonic seizures, clonic seizures, tonic-clonic seizures, absence seizures, or myoclonic seizures.
10. The method of claim 7 , wherein the seizures are atonic seizures, tonic seizures, clonic seizures, tonic-clonic seizures, absence seizures, or myoclonic seizures.
11. The method of claim 8 , wherein the seizures are atonic seizures, tonic seizures, clonic seizures, tonic-clonic seizures, absence seizures, or myoclonic seizures.
12. The method of claim 4 , wherein the patient has Lennox-Gastaut syndrome.
13. The method of claim 12 , wherein the starting dose of CBD is increased to a dose ranging from about 10 mg/kg/day to about 20 mg/kg/day.
14. The method of claim 13 , wherein the administering reduces the number of seizures by at least 50% compared to the number of seizures experienced during a baseline period before CBD was administered.
15. The method of claim 14 , wherein the seizures are atonic seizures, tonic seizures, clonic seizures, tonic-clonic seizures, absence seizures, or myoclonic seizures.
16. The method of claim 4 , wherein the patient has Dravet syndrome.
17. The method of claim 16 , wherein the starting dose of CBD is increased to a dose ranging from about 10 mg/kg/day to about 20 mg/kg/day.
18. The method of claim 17 , wherein the administering reduces the number of seizures by at least 50% compared to the number of seizures experienced during a baseline period before CBD was administered.
19. The method of claim 18 , wherein the seizures are atonic seizures, tonic seizures, clonic seizures, tonic-clonic seizures, absence seizures, or myoclonic seizures.
20. The method of claim 4 , wherein the patient has Tuberous Sclerosis Complex.
21. The method of claim 20 , wherein the starting dose of CBD is increased to about 25 mg/kg/day.
22. The method of claim 21 , wherein the administering reduces the number of seizures by at least 50% compared to the number of seizures experienced during a baseline period before CBD was administered.
23. The method of claim 22 , wherein the seizures are atonic seizures, tonic seizures, clonic seizures, tonic-clonic seizures, absence seizures, or myoclonic seizures.
24. The method of claim 4 , wherein the patient has Doose Syndrome.
25. The method of claim 24 , wherein the starting dose of CBD is increased to a dose ranging from about 10 mg/kg/day to about 25 mg/kg/day.
26. The method of claim 25 , wherein the starting dose of CBD is increased to about 25 mg/kg/day.
27. The method of claim 26 , wherein the administering reduces the number of seizures by at least 50% compared to the number of seizures experienced during a baseline period before CBD was administered.
28. The method of claim 27 , wherein the seizures are atonic seizures, tonic seizures, clonic seizures, tonic-clonic seizures, absence seizures, or myoclonic seizures.
29. An oral pharmaceutical formulation comprising (a) a cannabidiol (CBD) drug substance, (b) sesame oil, (c) ethanol, and (d) favoring, sweetener, or a combination thereof,
wherein the CBD is present in the pharmaceutical formulation at a concentration ranging from about 90 mg/mL to about 110 mg/mL, and
wherein the drug substance comprises CBD and at least one of (i) cannabidivarin (CBDV) at not more than 1.0% w/w based on the weight of the drug substance, (ii) delta-9 tetrahydrocannabinol (Δ 9 THC) at not more than 0.15% w/w based on the weight of the drug substance, or (iii) cannabidiol-C4 (CBD-C4) at not more than 0.5% w/w based on the weight of the drug substance.
30. The oral pharmaceutical formulation of claim 29 , comprising flavoring and sweetener.
31. The oral pharmaceutical formulation of claim 29 , wherein:
the ethanol is present at a concentration of about 71.1 mg/ml to about 86.9 mg/mL.
32. The oral pharmaceutical formulation of claim 30 , wherein the sweetener is present at a concentration of about 0.45 mg/ml to about 0.55 mg/ml, and the flavoring is present at a concentration of about 0.18 mg/ml to about 0.22 mg/ml.